History of approvals for proteasome inhibitors bortezomib, carfilzomib and ixazomib
Treatment at first relapse in multiple myeloma: how to choose a drug?
Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years
Nivolumab and pembrolizumab and the current treatment landscape for Hodgkin lymphoma
The stories behind the advances in polycythemia vera